Gilead Sciences, Inc. (BVMF:GILD34)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of BRL 861.07 billion. The enterprise value is 940.69 billion.

Market Cap	861.07B
Enterprise Value	940.69B

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 12, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.30%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.92 and the forward PE ratio is 15.00.

PE Ratio	19.92
Forward PE	15.00
PS Ratio	5.55
PB Ratio	7.53
P/TBV Ratio	n/a
P/FCF Ratio	17.63
P/OCF Ratio	16.71
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.87, with an EV/FCF ratio of 19.27.

EV / Earnings	21.76
EV / Sales	5.83
EV / EBITDA	11.87
EV / EBIT	14.92
EV / FCF	19.27

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	8.81M
Profits Per Employee	2.46M
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 9.47 billion in taxes.

Income Tax	9.47B
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +23.70% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+23.70%
50-Day Moving Average	320.54
200-Day Moving Average	301.15
Relative Strength Index (RSI)	64.15
Average Volume (20 Days)	291

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.46

Income Statement

In the last 12 months, Gilead Sciences had revenue of BRL 155.02 billion and earned 43.22 billion in profits. Earnings per share was 34.23.

Revenue	155.02B
Gross Profit	122.02B
Operating Income	60.60B
Pretax Income	52.69B
Net Income	43.22B
EBITDA	75.34B
EBIT	60.60B
Earnings Per Share (EPS)	34.23

Balance Sheet

The company has 45.25 billion in cash and 132.92 billion in debt, giving a net cash position of -76.99 billion.

Cash & Cash Equivalents	45.25B
Total Debt	132.92B
Net Cash	-76.99B
Net Cash Per Share	n/a
Equity (Book Value)	114.35B
Book Value Per Share	92.43
Working Capital	29.72B

Cash Flow

In the last 12 months, operating cash flow was 51.52 billion and capital expenditures -2.69 billion, giving a free cash flow of 48.83 billion.

Operating Cash Flow	51.52B
Capital Expenditures	-2.69B
Free Cash Flow	48.83B
FCF Per Share	n/a

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 5.85, which amounts to a dividend yield of 1.69%.

Dividend Per Share	5.85
Dividend Yield	1.69%
Dividend Growth (YoY)	0.91%
Years of Dividend Growth	1
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	0.66%
Earnings Yield	5.02%
FCF Yield	5.67%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7